Clear Street Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $12.
Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $12.